Corporate Presentation

Rare diseases SBS Glepaglutide significantly reduced weekly PS volume at Week 24 versus placebo in the EASE SBS-1 trial* ZEAL& ZEALAND PHARMA PS volume (I/week) Change from baseline Notes: 0 -1 T BL WI W2 W4 Glepa 10 mg TW (N=35) - Glepa 10 mg OW (N=35) Placebo (N=36) In anatomical subgroup analysis for patients without and with colon-in-continuity, the mean PS volume reduction at week 24 was -5.63 L/week and -4.77 L/week, respectively T W8 W12 Weeks W16 W20 W24 *) Results presented by Palle B. Jeppesen at the ASPEN 2023 Nutrition Science & Practice Conference in April 2023. -2.85 L/week Clinical response was significantly higher with twice weekly glepaglutide compared to placebo (p=0.0243): • 65.7% twice weekly glepaglutide 45.7% once weekly glepaglutide • 38.9% placebo group 9 patients treated with glepaglutide discontinued PS during the trial • • -5.13 L/week p=0.0039 14% (n=5) twice weekly glepaglutide 11% (n=4) once weekly glepaglutide • no patients receiving placebo Glepaglutide appeared to be well-tolerated in the trial • Most frequently reported adverse events were injection site reactions and gastrointestinal events 40 40

View entire presentation